Neil R Cashman

This inventor holds 36 USPTO granted patents and 23 published patent applications, plus 6 CIPO patents and 9 EPO patents, primarily in Antibody Therapeutics. Top assignees: The University of British Columbia, Amorfix Life Sciences Limited, Promis Neurosciences Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Neil R Cashman. Retrieved from https://idiyas.com/inventor/neil-r-cashman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 23)

% Patents Active = 61.1

CIPO Patents = 6 (Patent Applications = 19)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 1.9

ph-index = 7

Forward Citations = 129(Granted Patents)

Location History:

Montréal, Québec, CA (2002)
British Columbia, CA (2008)
Saskatoon, CA (2017)
Vancouver, CA (2010 - 2024)

Company Filing History:

16 out of 963

The University of British Columbia

patents

10 out of 10

Amorfix Life Sciences Limited

patents

9 out of 9

Promis Neurosciences Inc.

patents

4. 3 out of 213

University of Saskatchewan

patents

5. 2 out of 312

University Health Network

patents

6. 1 out of 14

Helix Biopharma Corporation

patents

7. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Misfolded Proteins

Amyloid-Beta

Antibodies

ALS Diagnostics

Cyclic Peptides

Prion Diseases

Epitopes

TDP-43

Oligomers

Conformational Epitopes

Neurodegenerative Disorders

Therapeutic Compositions

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559548 - ANTIBODIES TO MISFOLDED TDP-43 AND METHODS OF USE (2026-02-24),

2. 12404321 - Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof (2025-09-02),

3. 12286469 - Humanized antibodies binding to amyloid-beta (A-beta) (2025-04-29),

4. 12173055 - N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto (2024-12-24),

5. 12071472 - Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers (2024-08-27),

6. 11970522 - Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide (2024-04-30),

7. 11905318 - Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide (2024-02-20),

8. 11779629 - Compositions comprising cyclic peptides derived from an A-beta peptide (2023-10-10),

9. 11214613 - Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto (2022-01-04),

10. 10774120 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-09-15),

11. 10772969 - N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto (2020-09-15),

12. 10759837 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-09-01),

13. 10751382 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-08-25),

14. 10475525 - Methods and systems for predicting misfolded protein epitopes (2019-11-12),

15. 10053510 - FasR antibodies and methods of use (2018-08-21),

Title: The Innovative Journey of Neil R Cashman

Introduction: Neil R Cashman is a renowned inventor based in Vancouver, Canada, known for his groundbreaking contributions to various fields.

Latest Patents: Neil R Cashman holds several patents in the areas of biotechnology, medical devices, and environmental technologies, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over three decades, Neil R Cashman has worked on numerous projects that have revolutionized the industry, earning him a reputation as a visionary in the field of innovation.

Collaborations: Throughout his career, Neil R Cashman has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge sharing.

Conclusion: Neil R Cashman's passion for pushing the boundaries of technology and science continues to inspire the next generation of inventors and innovators globally.

Profile summary based on public USPTO records.